EGFR-IN-182
EGFR-IN-182 (Compound 4) is an EGFR inhibitor with an IC50 value of 199 nM. EGFR-IN-182 inhibits HSP90 and PI3K, with IC50 values of 5.007 and 13.596 μM respectively. EGFR-IN-182 exhibits strong anti-proliferative activity against MCF-7 and MDA-MB-231 cells. EGFR-IN-182 downregulates Cyclin D1, inducing cell cycle arrest; it enhances the activity of caspase-9, inducing cell apoptosis. EGFR-IN-182 downregulates the expressions of ERK and AKT. EGFR-IN-182 can be used for research on breast cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C25H18N8
- 分子量:430.46
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
EGFR 199 nM (IC50) |
HSP90 5.007 μM (IC50) |
PI3K 13.596 μM (IC50) |
Caspase 9 |
ERK |
Akt |
化学情報
-
分子量 430.46
-
分子式 C25H18N8
-
SMILES
N1(CC2=CC=CC=C2)C3=NC(N/N=C/C4=NC(C=CC=C5)=C5N=C4)=NN=C3C6=C1C=CC=C6
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- EGFR-IN-182
- EGFR
- HSP
- PI3K
- Caspase
- Apoptosis
- CDK
- ERK
- Akt
- Triazino[5,6-b]indole-hydrazones
- Triazino[5,6-b]indole-fused heterocyclic hybrids
- EGFR enzyme inhibition
- Hsp90 inhibition
- PI3K-AKT signaling
- ERK/AKT signaling
- Caspase-9 activation
- In silico docking study
- Cancer drug design
- Multi-target inhibitors in cancer therapy
- Inhibitor
- inhibitor
- inhibit